The in vitro antimicrobial activity of DU-6859a developed in Japan against a total of 201 isolates of respiratory pathogens including Mycobacteriaceae was determined. The minimum inhibitory concentrations (MIC's) of DU-6859a, ofloxacin, sparfloxacin, ciprofloxacin and rifampicin for 20 strains each of methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA). Escherichia coli. Enterobacter cloacae, Serratia marcescens and Pseudomonas aeruginosa, 7 strains of Haemophilus influenzae, 19 strains each of Klebsiella pneumoniae and Mycobacterium avium, 21 strains of RFP-susceptible Mycobacterium tuberculosis and 15 strains of RFP-resistant M. tuberculosis were determined by the micro- broth dilution method using the Dynatech MIC 2000 system. The MIC90's of DU-6859a for the above species were ≤0.06, 1, ≤0.06, 0.12, 0.25, 0.5, ≤0.06, 0.12, 8, 0.25 and 4 μg/ml respectively. DU-6859a was 2 to 16 times as active as the other agents against the species other than H. influenzae, E. coli, K. pneumoniae and E. cloacae. DU-6859a was as active as ofloxacin and ciprofloxacin against the latter four species. DU-6859a was as active as RFP and 4 to 8 times as active as ofloxacin and ciprofloxacin against RFP- susceptible M. tuberculosis. DU-6859a was 4 to 64 times as active as other agents against M. avium and RFP-resistant M. tuberculosis. We conclude from the above results that DU-6859a is one of the most useful quinolone agents for oral use as a drug of first choice in the treatment of respiratory infections.
|Number of pages||4|
|Journal||Japanese Journal of Chemotherapy|
|Publication status||Published - 1996 Nov 1|
ASJC Scopus subject areas
- Pharmacology (medical)